Loading
Donor bone marrow stromal cells given to children whose acute graft-versus-host disease no longer responds to steroids, the first mesenchymal stromal cell therapy approved in the United States.
Remestemcel-L is a suspension of culture-expanded mesenchymal stromal cells from the bone marrow of healthy adult donors. The cells dampen the T-cell attack on skin, gut and liver that defines acute graft-versus-host disease after an allogeneic stem cell transplant. The FDA approved it in December 2024 for steroid-refractory acute graft-versus-host disease in children aged two months and older, on a single-arm trial in which most children responded within a month. It is given intravenously twice a week for four weeks and is the first mesenchymal stromal cell product approved in the United States.
Mesenchymal stromal cells secrete anti-inflammatory factors and suppress activated T cells, reducing tissue damage in acute graft-versus-host disease.
1.Remestemcel-L slips into a pocket on its target.
| Region | Year | Indication |
|---|---|---|
| US | 2024 | Steroid-refractory acute graft-versus-host disease in children aged two months and older |
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"Remestemcel-L" OR ABSTRACT:"Remestemcel-L" OR TITLE:"Ryoncil" OR ABSTRACT:"Ryoncil") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Remestemcel-L, not a curated reading list.
Shares When steroids fail: ruxolitinib for steroid-refractory GvHD, Graft-versus-host disease (GVHD) and graft-versus-leukaemia.
Shares When steroids fail: ruxolitinib for steroid-refractory GvHD, Graft-versus-host disease (GVHD) and graft-versus-leukaemia.
Shares When steroids fail: ruxolitinib for steroid-refractory GvHD, Graft-versus-host disease (GVHD) and graft-versus-leukaemia.
Shares When steroids fail: ruxolitinib for steroid-refractory GvHD, Graft-versus-host disease (GVHD) and graft-versus-leukaemia.
Shares When steroids fail: ruxolitinib for steroid-refractory GvHD, Graft-versus-host disease (GVHD) and graft-versus-leukaemia.
Shares A phase 3, single-arm, prospective study of remestemcel-L, ex vivo culture-expanded adult human mesenchymal stromal cells for the treatment of pediatric patients who failed to respond to steroid treatment for acute graft-versus-host disease, MSB-GVHD001, Graft-versus-host disease (GVHD) and graft-versus-leukaemia.
Shares When steroids fail: ruxolitinib for steroid-refractory GvHD, Graft-versus-host disease (GVHD) and graft-versus-leukaemia.
Shares When steroids fail: ruxolitinib for steroid-refractory GvHD, Graft-versus-host disease (GVHD) and graft-versus-leukaemia.